Ngf for the prevention of demyelination in the nervous system
CA 2347335 A1 · Owner: Unger, Jurgen · Inventors: Hauser, Stephen; Genain, Claude; Bartke, Ilse
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention pertains to the discovery that nerve growth factor (NGF) is capable, of preventing further demyelination of nervous tissue in pathologies characterized by the, demyelination of nervous tissue (e.g. multiple sclerosis). In particular this , invention pertains to, the discovery that NGF will downregulate the production of interferon .gamma. by T cells infiltrating, the central nervous system and/or upregulate IL-10 production by glial cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 11, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 11, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 11, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.